Radiation Oncology/Drugs/Concurrent chemo



Concurrent chemo-RT schedules


Section Site Chemo RT Rationale
CNS Glioblastoma: adjuvant Temozolomide 75 mg/m2 daily 46 + 14 = 60 Gy EORTC 26981
GI Esophagus: neoadjuvant Cisplatin 100 mg/m2 D1, D29 + C.I. 5-FU 1000 mg/m2 D1-4, D29-32 45 + 5.4 = 50.4 Gy CALGB 9781
GI Gastric: adjuvant Bolus 5-FU 400 mg/m2 + LV 20 mg/m2 first 4 and last 3 days of RT 45 Gy INT 0116
GI Pancreas: adjuvant C.I. 5-FU 250 mg/m2 daily 45 + 5.4 = 50.4 Gy NCCN
GI Rectum: neoadjuvant C.I. 5-FU 225 mg/m2 daily 45 + 5.4 = 50.4 Gy NCCN
GI Rectum: adjuvant C.I. 5-FU 225 mg/m2 daily 45 + 9.0 = 54 Gy NCCN
GI Anal: definitive C.I. 5-FU 1000 mg/m2 D1-4, D29-32; mitomycin 10 mg/m2 D1 and D29 30.6 + 14.4 +/- 5.4-15 Gy = 45-59 Gy RTOG 98-11
GU Prostate: definitive Lupron 7.5 mg IM every month and flutamide 250 mg TID 70 (to 80) Gy Harvard
GYN Cervix: adjuvant Cisplatin 70 mg/m2 and C.I. 5-FU 1000 mg/m2 Q3W 49.3 Gy GOG 109
GYN Cervix: definitive Cisplatin 40 mg/m2 weekly 80-85 Gy Point A GOG 120
H&N Head & Neck: adjuvant Cisplatin 100 mg/m2 Q3W 60-66 Gy RTOG 95-01
Peds Medulloblastoma: adjuvant Vincristine 1.5 mg/m2 weekly 55. 8 Gy CCG A9961
Thorax NSCLC: neoadjuvant Cisplatin 50 mg/m2 D1,8,29,36 and etoposide 50 mg/m2 D1-5,29-33 45 Gy INT-0139
Thorax NSCLC: definitive Cisplatin 50 mg/m2 D1,8,29,36 and etoposide 50 mg/m2 D1-5,29-33 66 Gy NCCN
Thorax SCLC: definitive Cisplatin 60 mg/m2 D1 and etoposide 120 mg/m2 D1-3 Q3W 45 Gy BID INT-0096